Affimed Reports Progress on Key Clinical Development Programs
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
IND application submitted for first-in-human study of AFM24, a bispecific EGFR/CD16A innate cell engager for solid tumorsFDA clearance of IND for first clinical study of a stable complex of AFM13 pre-mixed with cord blood-derived allogeneic NK cells in patients with relapsed/refractory CD30-positive lymphoid malignanciesRegistration-directed Phase 2 study of AFM13 on track to start this quarter, supported by data confirming single-agent activity of AFM13 in CD30-positive lymphoma patients with an objective response rate of 50% Heidelberg, Germany, October 15, 2019 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company committed to giving patients back their innate ability to fight cancer, today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a first-in-human Phase 1/2a study of AFM24. The initial goal of the study is to determine the maximum tolerated dose and recommended
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)GlobeNewswire
- Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $20.00 to $15.00. They now have an "overweight" rating on the stock.MarketBeat
- Affimed (NASDAQ: AFMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)GlobeNewswire
- Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerGlobeNewswire
AFMD
Earnings
- 11/14/24 - Beat
AFMD
Sec Filings
- 12/17/24 - Form 6-K
- 11/14/24 - Form 6-K
- 11/12/24 - Form EFFECT
- AFMD's page on the SEC website